
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and to modernize healthcare systems so that patients benefit from durable, potentially curative treatments.
As the global voice of the sector, we represent more than 475 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
As the voice of the sector, ARM takes the lead on educating stakeholders on policy issues affecting the development of and patient access to regenerative medicines. For a full list of ARM’s presentations and publications, click here.
Comments
The Alliance for Regenerative Medicine (ARM) appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) proposed payment updates to the fiscal year 2024 Hospital Inpatient Prospective Payment System (Proposed Rule).